Early identification of the off-target activity of compounds, or secondary pharmacology, is important for guiding the lead selection and avoiding attrition of compounds due to safety risks. Assay panels designed to rapidly achieve this goal are a key safety component of all drug-hunting programs. Read the attached paper to learn how 4 major pharmaceutical companies collaborated to share the rationale, strategies, and methodologies for in vitro secondary pharmacology profiling